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Abstract
Background: In India, the Revised National Tuberculosis Control Programme (RNTCP) has adopted the strategy of
examining two specimens during follow-up culture examinations to monitor the treatment response of multi-drug resistant
tuberculosis (MDR-TB) patients.
Objectives: To determine the incremental yield of the second sputum specimen during follow-up culture examinations
among patients with MDR-TB and the effect on case management on changing from two to one specimen follow-up
strategy.
Methods: A cross sectional record review of MDR-TB patients registered during 2008–09 under RNTCP was undertaken in
three MDR-TB treatment sites of India.
Results: Of 1721 pairs of follow-up sputum culture examinations done among 220 MDR-TB patients, 451(26%) were positive
with either of the two specimens; 29(1.7%) were culture positive only on the second specimen indicating the incremental
yield. To detect one additional culture positive result on the second specimen, 59 specimens needed to be processed. If we
had examined only one specimen, we would have missed 29 culture-positive results. By current RNTCP guidelines, however,
a single specimen policy would have altered case management in only 3(0.2%) instances, where patients would have missed
a one month extension of the intensive phase of MDR-TB treatment. There is no meaningful advantage in using two
specimens for the monitoring of MDR-TB patients. A single specimen policy could be safely implemented with negligible
clinical effect on MDR-TB patients and favourable resource implications for RNTCP.
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Introduction
In India, the estimated incidence of multi-drug resistant (MDR)
tuberculosis (TB) cases in 2009 was 99,000. [1] The Revised
National TB Control Programme (RNTCP) began implementing
the programmatic management of drug resistant tuberculosis
(PMDT) in a phased manner from 2007, and is rapidly scaling up
PMDT services. By the end of 2011, RNTCP had initiated 6994
patients on MDR-TB treatment [2].
In accordance with international and national guidelines, the
progress of each patient during MDR-TB treatment is monitored
by sputum culture at a Culture and Drug susceptibility testing
(C&DST) laboratory accredited by the national programme. The
purpose of follow-up culture monitoring is to assess the response to
MDR-TB therapy, in order to guide treatment adjustments. A
positive culture indicates poor response to therapy; conversely
consistently negative cultures indicate good response. Although
collection of two sputum specimens to maximize culture recovery
has been recommended for the diagnosis of MDR-TB cases and in
international guidelines for the surveillance of drug-resistant
tuberculosis, international guidelines are silent as to the number
of sputum specimens recommended for follow-up culture exam-
inations in MDR-TB [3–4].
RNTCP in national PMDT guidelines has chosen to collect two
specimens for both diagnosis of MDR-TB and for follow-up
culture monitoring. The schedule for monitoring involves exam-
ining two sputum specimens at months 3, 4, 5, 6, 7, 9, 12, 15, 18,
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21, 24 (11 monitoring follow-ups) (Table 1) [5]. The first and
second specimens are recorded as ‘A’ and ‘B’ specimens
respectively in the C&DST register. The rationale for performing
two specimens for sputum culture at each follow-up visit is to have
high sensitivity for the detection of positive cases which would have
an impact both programmatically and on case management of
multi-drug resistant TB patients especially in the intensive phase.
The disadvantage is that large numbers of specimens have to be
examined in restricted laboratory capacity settings, with unknown
additional impact of second specimen on patient management.
With the current follow-up schedule and policy of examining two
specimens during every follow-up of an MDR-TB patient, and
given the rapid expansion of PMDT services in the country, the
RNTCP has estimated approximately 880,000 thousand follow-up
sputum culture examinations will be required, each requiring two
sputum specimens [2].
A single-specimen policy for follow-up culture examinations
would be expected to reduce patient inconvenience, the burden of
specimens requiring processing in laboratories and costs. This in
turn would mean more available bandwidth for the processing of
diagnostic specimens for the detection of MDR-TB. Despite these
broad ramifications, there was no information to guide this policy
decision. We conducted a retrospective study at three MDR-TB
treatment sites in India to determine the incremental yield of a
second sputum specimen for culture during follow-up examina-
tions of MDR-TB patients registered during 2008–09 and to
determine the impact of changing from two to a single specimen
follow-up strategy on case management.
Methods
Design
This is a cross sectional study involving review of programme
records and registers.
Setting
Under India’s RNTCP, the diagnosis of MDR-TB is made by
doing Culture and Drug Susceptibility Testing (C&DST) on
patients who fail RNTCP treatment regimens. The diagnosed
MDR-TB patients undergo pre-treatment evaluation before
starting MDR-TB treatment at MDR-TB treatment sites where
the patient is registered, started on treatment and monitored in
hospital for a period of at least seven days before referral to
domiciliary treatment.
Treatment is given in two phases, Intensive (IP) and continu-
ation (CP). The total duration of treatment for regimen of MDR-
TB is 24–27 months, depending on the IP duration which should
be given for at least six months. Patients will be considered culture
converted after having two consecutive negative cultures taken at
least one month apart in IP. After six months of treatment,
patients are reviewed and treatment changed to CP if both the 4th
and 5th month culture results are negative. If either or both 4th–5th
month culture results remain positive, treatment is extended by
one month. Extension of IP beyond 1 month will be decided on
the results of sputum culture of 5th or 6th and 6th or 7th months. If
the 4th month culture is still awaited after 6 months of treatment,
the IP is extended until the result is available, with further
treatment being decided according to the culture results. The IP
can be extended up to a maximum of 3 months after which the
patient will be initiated on CP irrespective of the culture result.
The recommended duration of CP is 18 months.
For follow-up examinations, the specimens are collected and
transported under cold chain conditions from the respective
District TB Centre and examined by smear and culture at least
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30 days apart from the 3rd to 7th month of treatment (i.e., at the
end of the months 3,4,5,6 and 7) and at 3 monthly intervals from
the 9th month onwards till the completion of treatment (i.e., at the
end of the months 9, 12, 15, 18, 21 and 24). All the specimens
were subjected to solid culture. During the study period, the C &
DST laboratories of these study sites were accredited by RNTCP
for solid culture technology. The WHO standardised treatment
outcome definitions are used in RNTCP.
All MDR-TB patients registered at three MDR-TB treatment
sites during 2008–09, and whose treatment outcome were reported
by end of 2011 were included in the study. The three sites were
Hyderabad (Andhra Pradesh), Ahmedabad (Gujarat) and Jaipur
(Rajasthan).
Variables and Data Collection
Variables collected for each patient were patient name, DOTS-
plus TB number, age, sex, HIV status, date of registration, month
of follow-up, date and results of smear examination, date and
results of culture examination and treatment outcome. The
outcome variables were all culture results. Data were collected
into a structured proforma by the trained staff at MDR-TB
treatment sites and laboratories. The source of data was from
DOTS-plus TB register and C&DST laboratory register.
Analysis and Statistics
All the data was entered twice by independent data entry
operators trained for the purpose into an EpiData database. The
two databases were then compared for discrepancies and a final
database was created after correcting discrepancies by referring
the original records. This final database was then analyzed using
EpiData analysis software. Data were cross-tabulated and the
following were calculated: the proportion of follow-up examina-
tions which were culture positive, the proportion who were
positive on the second specimen only when the first specimen was
non positive (i.e., the ‘‘incremental yield’’ - X), and the its inverse
(1/X) was determined to calculate the number of second sputum
culture examinations, that were done to get one additional culture
positive case.
The longitudinal culture results of the MDR-TB patients were
then examined to estimate hypothetically, the impact of using the
results of single (first) specimen only on case management of
MDR-TB patients; specifically to find the number of patients who
would have missed IP extension, number who would have delayed
submission of specimens for second line drug susceptibility testing
and number who would have a different outcome declared or led
to a delay in declaration of outcome.
Ethics Approval
As this study was a record review of routinely collected RNTCP
data, informed consent of individual patients was deemed
unnecessary. The same was reviewed and approved by Central
TB Division, Ministry of Health and Family Welfare, India andthe
Ethics Advisory Group of International Union Against TB and
Lung Disease (The Union).
Results
A total of 220 MDR-TB patients registered at the three MDR-
TB treatment sites were included in the study. During their
treatment period 1763 pairs of follow-up culture examinations
were done. Data of 19 first culture examination results and 23
second culture examination results were not recorded and hence
results of remaining 1721 (98%) pairs were included in the
analysis.
Table 2. Incremental yield of second specimen during follow-up culture examinations among Multi Drug Resistant Tuberculosis
patients registered in 2008–09, India.
Total 1721
Culture results of first and second specimen
Negative-Negative 1226
Negative-Positive 18
Negative-Contaminated 4
Positive-Negative 28
Positive-Positive 390
Positive-Contaminated 4
Contaminated-Negative 8
Contaminated-Positive 11
Contaminated-Contaminated 32
Essential patterns of culture examination results
Positive-Any result 422
Non positive-Positive 29
Rest 1270
Number (Proportion) positive on any specimen 451 (26.2%)
Number (Proportion) positive on second specimen only: Incremental Yield 29 (1.7%)
95% Confidence Interval 1.0%–2.4%
Additional number of culture examinations to detect one positive result on second specimen 59
95% Confidence Interval 42–102
doi:10.1371/journal.pone.0045554.t002
2 vs 1 Follow-Up Cultures for MDR-TB Patients
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Incremental Yield of the Second Sputum Specimen for
Culture during Follow-up Visits
Of 1721 pairs of follow-up sputum culture examinations done
among 220 MDR-TB patients, 451(26%) were positive with either
of the two specimens; 29(1.7%) were culture positive only on the
second specimen indicating the incremental yield. (Table 2) To
detect one additional culture positive result on the second
specimen, 59(42–102) specimens needed to be processed.
The Effect on Case Management on Changing from Two
to Single Specimen Follow-up Strategy
As shown in Table 1, of 1721 follow-up examinations, there
were a total of 29 (1.7%) instances where we would have missed a
positive culture result had we adopted a single specimen strategy.
The results of serial follow-up culture results of MDR-TB patients
in whom we would have missed a positive culture had we
performed culture examination of only one specimen and the
possible impact on case management is shown in Table 3. In only
3 instances (0.2% of all follow-up examinations), the missed
positive cultures would have impacted on case management in
terms of failing to extend the intensive phase by one month. There
was no impact of missed positive cultures on declaration of
treatment outcome or initiating action for assessing second line
drug susceptibility testing.
Discussion
This is the first study describing the incremental yield of the
second sputum specimen during follow-up culture examinations of
MDR-TB patients and the impact on case management on
changing from two to single specimen follow-up strategy. The
strength of the study is that routine programme data was used
from the cohort of MDR-TB patients registered under RNTCP,
thus reflecting the operational reality. We have adhered to
STROBE guidelines on reporting [6].
These findings have the following programmatic implications.
First, the incremental yield of examining a second specimen was
very low at 1.7%, and it is pragmatically redundant to process
nearly 60 follow-up specimens to get one additional positive
culture. In resource limited settings with limited laboratory
capacity, reducing to single specimen follow-up will decrease the
laboratory workload considerably and helps in prioritizing the
effort towards examining more diagnostic specimens [7]. This will
help in diagnosing more MDR-TB patients who are in need to
treatment as currently only 3–4% of all estimated MDR-TB cases
in the country are on treatment. In addition, there would be
reduced direct and indirect logistics cost involved in sputum
transportation and processing. Patient treatment adherence may
improve if they are relieved of the burden of extra visits to health
facilities to provide sputum specimens. This we believe is a crucial
step in advancing towards realising the ambitious plan of RNTCP
to achieve universal access to diagnosis and treatment of all MDR-
TB patients in the country.
Table 3. Impact of examining only one specimen instead of two for culture during follow-up of multi-drug resistant tuberculosis
patients, India, 2008–09.
Patient ID
Results of monthly serial culture examinations during the
course of MDR-TB treatment* Final treatment outcome Clinical impact
1-2-002 –011101–-1–1–-1-1––-1– Failure No
1-2-007 –11111111–––––––––- Death No
1-2-008 –00000-1–1–1111–0–1––- Failure No
1-2-034 –0100100––-0–1–1–––– Death No
1-2-040 –-10000-1–1–1–1––––– Death No
1-2-049 –-111111––-1–1–1–1–1– Failure No
1-2-056 –00001-0–0–0–0–0–0––- Cured No
1-2-061 –10-0–1–0–0––-0–0––- Cured No
1-2-065 –1111–1-1–-1–1–1–1––- Failure No
1-2-066 –100–-0–0–0-1–-1–1––- Failure No
2-1-009 –1111–1–1–0–1–1–1–1– Failure No
2-2-001 –11100000-0–0–0–0–0–0– Cured No
2-2-008 –1011––––1––––––– Death Yes**
2-2-010 –1110100-1–1–0–1––––- Treatment completed No
2-2-015 –11111110-1–0–1–––––- Death No
2-2-016 –1000–0–1–1–1–1–1––- Failure No
2-2-022 –11101-1–1–1–1––-1–1– Failure No
2-2-023 –111000101–1–1–1–1–1–- Failure Yes**
2-2-024 –1111111–1–1–1–––0–– Treatment completed No
2-2-026 –1111-100-0–0–-0-0–0–0– Cured Yes**
*These are the results of follow-up culture examinations starting from month 1 to month 29 as applicable. 1 indicates culture positive result, 0 indicates culture negative
result and ‘‘–’’ indicates either follow-up not done or not applicable; 1 indicates positive culture results which would have been missed if only one specimen had been
examined.
**Would have missed extending Intensive phase of treatment by one month.
doi:10.1371/journal.pone.0045554.t003
2 vs 1 Follow-Up Cultures for MDR-TB Patients
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What is the Effect of Single Specimen Follow-up Strategy
on Clinical Case Management?
The effect of the single specimen follow-up strategy was limited
to a handful of missed positive cultures which in turn would have
had very little effect on MDR-TB case management. Effectively,
the collection transportation and laboratory processing of 1721
second follow-up cultures led to 3 instances where the intensive
phase of treatment is extended. Reassuringly, there were no
observed lost opportunities for the detection of treatment failure
and referral for second line drug susceptibility testing. Rather, any
possible events would have been triggered by an earlier or a later
follow-up culture examination. With serial cultures, such events
would be likely caught at the next or preceeding follow-up
cultures. This is very convincing evidence to move towards single
specimen follow-up culture examination and urge RNTCP to
consider policy change in this regard.
Though, we did not find any instance in this cohort of MDR-
TB patients, the other possible impact on case management of a
missed positive culture is that we miss the opportunity to identify
treatment failure early and initiate steps to examine if the patient
has extensively drug resistant tuberculosis. This possibility can be
greatly minimized if national programme takes a policy decision to
examine all the specimens for second line DST right at the
beginning of treatment. However, the current capacity of RNTCP
for second line drug susceptibility testing is limited and needs to be
strengthened further.
This study had some limitations. As in any record–based study,
it is limited by the retrospective nature of the data, which may
have been inaccurate or incomplete; however, routine supervision
and monitoring within the programme is likely to have reduced
this. [8] The study is also limited by the fact that the first follow-up
specimen sent for C&DST may either be spot or early morning
sputum specimen as the time of sputum collection was not
documented by health staff.
In conclusion, there is no meaningful advantage in using two
specimens for the monitoring of MDR-TB patients. A single
specimen policy could be safely implemented with negligible
clinical effect on MDR-TB patients and favourable resource
implications for RNTCP.
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